A Prospective, Single-Arm Clinical Study on the Treatment of HR+/HER2- Breast Cancer With Neoadjuvant Chemotherapy Combined With Anlotinib and Benmelstobart Monoclonal Antibody
Latest Information Update: 21 Mar 2025
At a glance
- Drugs Benmelstobart (Primary) ; Catequentinib (Primary) ; Cyclophosphamide (Primary) ; Epirubicin (Primary) ; Paclitaxel (Primary)
- Indications Breast ductal carcinoma; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms NEOTORCH-BREAST03
- 21 Mar 2025 New trial record